 | • レポートコード：MRC2303L171 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、243ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に7,295.13百万ドルであった世界の網膜疾患治療市場規模が2022年に7,927.17百万ドルとなり、2027年までに年平均8.84％拡大して12,127.96百万ドルに達すると予測されています。本書では、網膜疾患治療の世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（糖尿病性網膜症、黄斑変性症）分析、剤形別（カプセル＆錠剤、目薬、眼科用液剤、ジェル、軟膏）分析、流通チャネル別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、AbbVie Inc.、Abeona Therapeutics、Apellis Pharmaceuticals、Applied Genetic Technologies Corporation,、Bausch & Lomb, Inc.、Bayer AG、Bluebird bio Inc、F. Hoffmann-La Roche AG、Genentech, Inc.、GlaxoSmithKline PLC、Graybug Vision, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の網膜疾患治療市場規模：種類別 - 糖尿病性網膜症治療の市場規模 - 黄斑変性症治療の市場規模 ・世界の網膜疾患治療市場規模：剤形別 - カプセル＆錠剤の市場規模 - 目薬の市場規模 - 眼科用液剤の市場規模 - ジェルの市場規模 - 軟膏の市場規模 ・世界の網膜疾患治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の網膜疾患治療市場規模：地域別 - 南北アメリカの網膜疾患治療市場規模 アメリカの網膜疾患治療市場規模 カナダの網膜疾患治療市場規模 ブラジルの網膜疾患治療市場規模 ... - アジア太平洋の網膜疾患治療市場規模 日本の網膜疾患治療市場規模 中国の網膜疾患治療市場規模 インドの網膜疾患治療市場規模 韓国の網膜疾患治療市場規模 台湾の網膜疾患治療市場規模 ... - ヨーロッパ/中東/アフリカの網膜疾患治療市場規模 イギリスの網膜疾患治療市場規模 ドイツの網膜疾患治療市場規模 フランスの網膜疾患治療市場規模 ロシアの網膜疾患治療市場規模 ... - その他地域の網膜疾患治療市場規模 ・競争状況 ・企業情報 |
The Global Retinal Disorder Treatment Market size was estimated at USD 7,295.13 million in 2021 and expected to reach USD 7,927.17 million in 2022, and is projected to grow at a CAGR 8.84% to reach USD 12,127.96 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Retinal Disorder Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Diabetic Retinopathy and Macular Degeneration. The Macular Degeneration is further studied across Dry Macular Degeneration and Wet Macular Degeneration.
Based on Dosage Form, the market was studied across Capsules & Tablets, Eye Drops, Eye Solutions, Gels, and Ointments.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Retinal Disorder Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Retinal Disorder Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Retinal Disorder Treatment Market, including AbbVie Inc., Abeona Therapeutics, Apellis Pharmaceuticals, Applied Genetic Technologies Corporation,, Bausch & Lomb, Inc., Bayer AG, Bluebird bio Inc, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline PLC, Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd, Novartis International AG, ONL Therapeutics, Inc., Opthea, Oxford BioMedica PLC, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Transgene SA.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Retinal Disorder Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Retinal Disorder Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Retinal Disorder Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Retinal Disorder Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Retinal Disorder Treatment Market?
6. What is the market share of the leading vendors in the Global Retinal Disorder Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Retinal Disorder Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing funding by regulatory bodies for research on ocular disorders
5.1.1.2. Increasing prevalence of retinal disorders globally
5.1.1.3. Rising elderly population coupled with macular degeneration
5.1.2. Restraints
5.1.2.1. High cost involved in research and development activities
5.1.3. Opportunities
5.1.3.1. Technological innovations and advancements in treatments
5.1.3.2. Growing strategic collaborations and commercialization of novel products
5.1.4. Challenges
5.1.4.1. Probable complications in the eye
5.2. Cumulative Impact of COVID-19
6. Retinal Disorder Treatment Market, by Type
6.1. Introduction
6.2. Diabetic Retinopathy
6.3. Macular Degeneration
6.4.1. Dry Macular Degeneration
6.4.2. Wet Macular Degeneration
7. Retinal Disorder Treatment Market, by Dosage Form
7.1. Introduction
7.2. Capsules & Tablets
7.3. Eye Drops
7.4. Eye Solutions
7.5. Gels
7.6. Ointments
8. Retinal Disorder Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Americas Retinal Disorder Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Retinal Disorder Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Retinal Disorder Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abeona Therapeutics
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Apellis Pharmaceuticals
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Applied Genetic Technologies Corporation,
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bausch & Lomb, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer AG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bluebird bio Inc
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. F. Hoffmann-La Roche AG
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Genentech, Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. GlaxoSmithKline PLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Graybug Vision, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Kubota Pharmaceutical Holdings Co., Ltd
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis International AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. ONL Therapeutics, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Opthea
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Oxford BioMedica PLC
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Oxurion NV
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Pfizer, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Regeneron Pharmaceuticals, Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Santen Pharmaceutical Co., Ltd.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Spark Therapeutics, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Takeda Pharmaceutical Company Limited
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Transgene SA
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing